How to Administer Retatrutide: Injection Guide, Dosing & Safety

How to administer retatrutide is an important question for anyone enrolled in a clinical trial investigating this novel triple agonist therapy. Retatrutide (LY3437943) is an investigational once-weekly subcutaneous injection targeting GLP-1, GIP, and glucagon receptors simultaneously, currently under evaluation for obesity and type 2 diabetes. It is not yet licensed by the MHRA or EMA and is only available within regulated clinical trials. This article outlines the injection technique, site selection, dosing schedule, storage requirements, and safety considerations based on Phase 2 trial protocols and established UK subcutaneous injection guidance.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, under Phase 2 evaluation for obesity and type 2 diabetes; it is not licensed by the MHRA or EMA and is only available within regulated clinical trials.

Retatrutide (LY3437943) is an investigational injectable medication under clinical development for the management of obesity and type 2 diabetes mellitus. It belongs to a novel class of agents known as triple agonists, targeting three incretin and metabolic receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist).^[2][9]

By activating GLP-1 receptors, retatrutide is thought to enhance insulin secretion in a glucose-dependent manner, suppress glucagon release, and reduce appetite.^[7][8] GIP receptor activation may further support insulin sensitivity and fat metabolism, whilst glucagon receptor agonism is hypothesised to promote energy expenditure and reduce hepatic fat accumulation.^[4][10] These are mechanistic hypotheses or early findings only; robust confirmation in humans for retatrutide specifically is still emerging.

A Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023) reported substantial reductions in body weight in participants with obesity. Separate Phase 2 data in people with type 2 diabetes have also been reported (Rosenstock et al., 2023, NEJM), suggesting improvements in glycaemic control; however, both sets of findings require confirmation in larger Phase 3 studies and should be interpreted with caution.

It is important to note that, as of the time of writing, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), as confirmed by the MHRA medicines database and the EMA medicines database. It is not currently available as a licensed medicine in the UK. Any use outside of approved clinical trials would be outside the scope of standard clinical practice. Patients should not attempt to obtain retatrutide from unregulated or overseas online suppliers, as the safety, quality, and authenticity of such products cannot be assured. Patients should always consult their GP or specialist before considering any unlicensed treatment, and should only receive retatrutide within the context of a regulated clinical trial or under appropriate medical supervision.

How to Inject Retatrutide: Step-by-Step Instructions

Retatrutide is administered by subcutaneous injection following hands-on training from the clinical trial team; the injection site is cleaned, skin is pinched, the needle inserted at 45 to 90 degrees, and the used device disposed of immediately in an approved sharps container.

Based on the administration protocols used in clinical trials, retatrutide is delivered as a subcutaneous injection, that is, injected into the fatty tissue just beneath the skin. The presentation of the investigational product (pre-filled pen, pre-filled syringe, or vial) may vary between trial sites and phases; always follow the device-specific instructions provided by your clinical trial team, and ensure you have received hands-on training before self-injecting.

The following steps reflect general best practice for subcutaneous self-injection, consistent with Royal College of Nursing (RCN) standards for subcutaneous injection technique and NHS patient-facing advice for similar injectable medicines.^[12][13] They are intended as a general reference only and do not replace your trial protocol or investigator's instructions.

Before you begin:

• Wash your hands thoroughly with soap and water for at least 20 seconds.

• Gather all necessary supplies: the trial-supplied device, a new sterile needle (if not pre-attached), alcohol swabs, and an approved sharps disposal container.

• Check the medication: inspect the solution for discolouration, cloudiness, or visible particles. Do not use if the solution appears abnormal.

• Check the expiry date and confirm the correct dose as instructed by your clinical team.

• If the device has been refrigerated, allow it to reach room temperature for the period specified in your trial instructions before injecting, as this may reduce discomfort. Do not assume a standard warm-up time; follow your protocol.

• Some devices require priming before first use; follow the device Instructions for Use provided by the trial team.

1. Administering the injection:
2. Clean the chosen injection site with an alcohol swab and allow it to dry completely.
3. Pinch a fold of skin gently between your thumb and forefinger.
4. Insert the needle at a 45 to 90 degree angle, depending on the needle length and the thickness of subcutaneous tissue at the site, as advised by your clinical team.
5. Press the plunger or activation button slowly and steadily until the full dose has been delivered.
6. Hold the needle in place for the number of seconds specified in your device instructions before withdrawing, to help ensure the full dose is absorbed.
7. Release the skin fold and apply gentle pressure with a clean swab; do not rub, as this may affect absorption.
8. Dispose of the used needle immediately in your approved sharps container. Never recap needles. Never share pens, needles, or any part of the injection device with another person.

Sharps disposal: Used needles and devices must be disposed of in an approved sharps container. Your clinical trial team will usually arrange or advise on sharps bin provision and collection. If you need further guidance, your GP surgery or local authority clinical waste service can help. Community pharmacy acceptance of sharps varies across the UK; confirm local arrangements with your trial team or GP before relying on this route.

Always follow the specific instructions provided by your clinical trial team or prescribing clinician, as device design and handling requirements vary between investigational products.

Choosing the Right Injection Site and Technique

The preferred sites are the abdomen (at least 5 cm from the navel), outer thigh, and outer upper arm; systematic rotation between sites is essential to prevent lipohypertrophy and maintain consistent drug absorption.

Selecting an appropriate injection site is important for consistent drug absorption and minimising local skin reactions. For subcutaneous injections such as retatrutide, the sites used in clinical trials, consistent with RCN and NHS guidance for similar agents, include:

• Abdomen: The area at least 5 cm away from the navel is the most commonly used site, offering a relatively large surface area and predictable absorption.

• Thigh: The outer, middle third of the thigh is suitable and easily accessible for self-injection.

• Upper arm: The outer aspect of the upper arm may be used; however, this site generally requires administration by a trained carer or healthcare professional unless the trial protocol and device specifically permit self-use at this location.

Rotation of injection sites is strongly recommended. Injecting repeatedly into the same location can lead to lipohypertrophy, a build-up of fatty tissue beneath the skin, which may impair drug absorption and lead to variable medication delivery. This is well established with insulin and is considered a relevant concern for subcutaneous peptide injections more broadly; it is recommended as general best practice for this route of administration. A systematic rotation pattern (for example, moving clockwise around the abdomen, or alternating between left and right thigh) helps minimise this risk. Your trial protocol takes precedence over any general guidance.

Avoid injecting into areas that are:

• Bruised, tender, or broken

• Affected by skin conditions such as psoriasis or eczema

• Near moles, scars, or areas of lipohypertrophy

Always use a new needle for every injection and do not inject through clothing. If you notice any persistent lumps, hardened areas, or skin changes at injection sites, report these to your clinical trial nurse or GP promptly.

Dosing Schedule and Storage Guidance

Retatrutide is injected once weekly on the same day each week, following a structured escalation schedule defined by the trial protocol; storage conditions are set by the trial sponsor and must not be inferred from other medicines.

In the Phase 2 clinical trials cited above (Jastreboff et al., 2023; Rosenstock et al., 2023), retatrutide was administered as a once-weekly subcutaneous injection, following a structured dose-escalation schedule. This approach is consistent with other GLP-1-based therapies and is designed to minimise gastrointestinal side effects whilst allowing the body to adjust gradually to the medication. In the obesity Phase 2 trial, doses studied ranged from 1 mg up to 12 mg weekly, with escalation occurring over several weeks under medical supervision. Dosing regimens vary between study arms and trial phases; the schedule applicable to you will be defined by your specific trial protocol, which may differ from the published trial arms.

Key points regarding the dosing schedule:

• Consistency: Injections should be administered on the same day each week, at any time of day, with or without food, unless your protocol specifies otherwise.

• Missed dose: If you miss a dose, do not attempt to manage this independently. Contact your clinical trial team for guidance, as missed-dose windows and instructions are defined by the trial protocol and may vary. Do not double-dose to compensate.

• Dose adjustments and treatment interruptions: These should only be made under the guidance of your supervising clinician or trial investigator. Interruptions may require re-titration per protocol.

Storage guidance: Because retatrutide is an investigational product, storage and handling requirements are defined by the trial sponsor, the pharmacy supplying the medication, and the Investigator's Brochure. Follow only the instructions on the pharmacy label or those provided by your clinical team; do not infer storage conditions from those of other medicines. If you are unsure about any aspect of storage or handling, contact your clinical trial team before using the medication.

Store all medicines out of the reach of children at all times.

Common Side Effects and What to Watch For

The most common side effects are gastrointestinal (nausea, vomiting, diarrhoea) and are usually mild to moderate during dose escalation; seek urgent help for signs of anaphylaxis, severe chest pain, or severe persistent abdominal pain.

As with other incretin-based therapies, retatrutide is associated with a range of side effects, the majority of which are gastrointestinal in nature and tend to be most pronounced during the dose-escalation phase. Data from Phase 2 trials (Jastreboff et al., 2023; Rosenstock et al., 2023) indicate that these effects are generally mild to moderate and transient.

Common side effects include:

• Nausea and vomiting

• Diarrhoea or constipation

• Reduced appetite

• Abdominal discomfort or bloating

• Injection site reactions (redness, itching, or mild swelling)

These effects can often be managed by eating smaller, lower-fat meals, avoiding lying down immediately after eating, staying well hydrated, and adhering to the gradual dose-escalation schedule.

Less common but clinically important effects observed in trials or considered potential class effects include:

• Heart rate increase: An elevation in resting heart rate was reported in Phase 2 trial data for retatrutide, consistent with a known class effect of GLP-1 receptor agonists. This should be monitored, particularly in individuals with pre-existing cardiovascular conditions.

• Hypoglycaemia: Based on Phase 2 trial data and the known pharmacology of GLP-1-based agents, the risk of low blood sugar is low when retatrutide is used alone but may increase if combined with insulin or sulfonylureas (for example, gliclazide or glibenclamide). If you take either of these medicines, discuss hypoglycaemia management with your clinical team.

• Dehydration and kidney strain: Persistent vomiting or diarrhoea can lead to dehydration and, in some cases, acute kidney injury. Maintain adequate fluid intake and seek medical review if you are unable to keep fluids down.

• Gallbladder-related issues: Rapid weight loss associated with this class of medication may increase the risk of gallstones.

Pregnancy, breastfeeding, and contraception: Retatrutide is an investigational medicine and its safety in pregnancy or breastfeeding has not been established. If you are pregnant, planning a pregnancy, or breastfeeding, inform your clinical trial team immediately. Trial protocols typically require effective contraception during participation; follow the guidance provided by your trial team.

Thyroid considerations: Preclinical studies in rodents, consistent with findings for other GLP-1 receptor agonists as a class, have raised theoretical concerns regarding thyroid C-cell tumours. No causal link has been established in humans for retatrutide or other GLP-1-based medicines. Nonetheless, individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) should discuss this with their clinician before enrolling in any trial involving this class of agent.^[19][20]

When to seek urgent help:

• Call 999 immediately if you experience signs of a severe allergic reaction (anaphylaxis): sudden rash, swelling of the face, lips, tongue or throat, or severe difficulty breathing.

• Call 999 if you experience severe chest pain or collapse.

• Call NHS 111 for urgent advice if your GP or clinical trial team is unavailable and you are concerned about symptoms that are not immediately life-threatening.

• Contact your GP or clinical trial team promptly if you experience: severe or persistent abdominal pain (which could indicate pancreatitis); significant changes in heart rate or palpitations; symptoms of low blood sugar (shakiness, sweating, confusion); or persistent vomiting preventing adequate fluid intake.

Reporting side effects: If you experience a suspected side effect whilst taking retatrutide outside a clinical trial, you or your healthcare professional can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the MHRA Yellow Card app. If you are participating in a clinical trial, report any suspected side effects to your trial team or study sponsor in the first instance, in accordance with your trial protocol.

Frequently Asked Questions